Fractyl Announces Closing Of $100 Million Series F Financing To Expand Clinical Development Programs In Type 2 Diabetes
Fractyl Announces Closing Of $100 Million Series F Financing To Expand Clinical Development Programs In Type 2 Diabetes
06/16/21, 10:08 AM
Location
lexingtonMoney raised
$100 million
Round Type
series f
Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the closing of a $100 million Series F financing. The financing was led by new investors Maverick Capital, M28 Capital, and Population Health Partners, with participation by other new and existing investors. As part of this financing, Marc Elia, founder of M28 Capital, and Clive Meanwell, M.D., Ph.D., executive chairman and founder of Population Health Partners, have joined Fractyl’s Board of Directors.
Company Info
Company
Fractyl Health
Location
lexington, south carolina, united states
Additional Info
Fractyl is pioneering treatments for metabolic diseases based on revolutionary scientific insights into the root causes of metabolic dysfunction. Fractyl’s lead program is Revita DMR, an outpatient endoscopic procedural therapy designed to treat insulin resistance in T2D. The company’s groundbreaking discoveries offer the potential to address other metabolic diseases in the future, including nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH), in an effort to reduce the global economic and healthcare burden of metabolic disease. Fractyl is a private biotechnology company based in Lexington, Mass. For more information, visit www.fractyl.com or www.twitter.com/FractylHealth